Dr. Bulman runs the Precision Antimicrobial Laboratory, which aims to devise novel therapeutic approaches that are capable of successfully treating infectious diseases while also suppressing the amplification of new resistance mechanisms. His laboratory is developing cutting-edge pharmacokinetic and pharmacodynamic treatment approaches for antibiotics to help combat multidrug-resistant bacteria. Implementing clinical pharmacokinetic data from patients, Dr. Bulman’s lab simulates the human exposures of antimicrobials in the laboratory to evaluate their pharmacodynamic effects.
His recent work has facilitated the resurrection of an old agent, polymyxin B, in preparation for continued clinical outbreaks of carbapenem-resistant Gram-negatives. He has also recently optimized combination therapies to combat mcr-1 and blaNDM harboring carbapenem-resistant E. coli. Dr. Bulman is also interested in optimizing the use of inhaled antibiotics for patients with pneumonia. Ongoing projects in Dr. Bulman’s laboratory are exploring patient specific treatment strategies for bacteria with genetically defined resistance mechanisms.
Lab Highlights Heading link
Recent updates from the Bulman Lab.
Dr. Bulman Leads Team to Highlight Key PK/PD Research Priorities Heading link
Dr. Bulman, in collaboration with leaders from 3 international infectious disease societies, led the development of a personal view article published in Lancet Microbe that sought to emphasize several key research priorities in antibiotic PK/PD. Although progress has been made in our quest to optimize the treatment of infections, additional research will be required to fully realize the potential of precision antibiotic therapy and its ability to improve patient outcomes. The article was also featured on ContagionLive.
Dr. Bulman Receives $3.66M R01- Among Largest R01's in the History of the UIC College of Pharmacy Heading link
Dr. Zackery Bulman recently received a $3.66 million, 5-year R01 grant as PI for his project titled, “Precise Combination Strategies Targeting Carbapenem-Resistant Klebsiella pneumoniae” (R01AI173064). This R01 is the largest R01 in the history of the UIC College of Pharmacy (based on NIH Reporter data). This project will develop new antibiotic combination treatment approaches for drug-resistant superbugs, which can cause serious infections associated with high mortality rates.